Sequoia Financial Advisors LLC Sells 186 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Sequoia Financial Advisors LLC reduced its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 21.8% during the 1st quarter, HoldingsChannel reports. The fund owned 667 shares of the biotechnology company’s stock after selling 186 shares during the period. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $206,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in UTHR. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 50 shares during the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics during the first quarter worth approximately $49,000. State of Wyoming bought a new stake in United Therapeutics during the fourth quarter worth approximately $62,000. Curat Global LLC bought a new stake in United Therapeutics during the first quarter worth approximately $63,000. Finally, Millstone Evans Group LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $67,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $294.57 on Friday. The firm has a market capitalization of $13.29 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 6.45 and a beta of 0.53. The stock has a 50 day moving average price of $301.21 and a 200 day moving average price of $322.53. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.17 earnings per share. Analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on UTHR shares. Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 11th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They set an “overweight” rating and a $405.00 target price on the stock. UBS Group cut their target price on United Therapeutics from $410.00 to $385.00 and set a “buy” rating on the stock in a research note on Monday, June 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $386.15.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the company’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of the company’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company’s stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 80,681 shares of company stock valued at $23,951,939 over the last 90 days. Insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.